questionsmedicales.fr
Cellules
Cellules épithéliales
Hépatocytes
Cellules HepG2
Cellules HepG2 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
2
Carcinome hépatocellulaire
Lignées cellulaires
Culture cellulaire
Microscopie
Symptômes
2
Symptômes
Cellules in vitro
Marqueurs tumoraux
Enzymes hépatiques
Prévention
2
Prévention des maladies
Composés bioactifs
Recherche préventive
Toxines
Traitements
2
Essais cliniques
Toxicité
Développement de médicaments
Mécanismes d'action
Complications
2
Mécanismes pathologiques
Complications hépatiques
Facteurs de risque
2
Facteurs de risque
Toxines
Évaluation des risques
Agents toxiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Cellules HepG2 : Questions médicales les plus fréquentes",
"headline": "Cellules HepG2 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Cellules HepG2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-11",
"dateModified": "2025-02-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Cellules HepG2"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Hépatocytes",
"url": "https://questionsmedicales.fr/mesh/D022781",
"about": {
"@type": "MedicalCondition",
"name": "Hépatocytes",
"code": {
"@type": "MedicalCode",
"code": "D022781",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A11.436.348"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Cellules HepG2",
"alternateName": "Hep G2 Cells",
"code": {
"@type": "MedicalCode",
"code": "D056945",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Wilson de Melo Cruvinel",
"url": "https://questionsmedicales.fr/author/Wilson%20de%20Melo%20Cruvinel",
"affiliation": {
"@type": "Organization",
"name": "School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil. melocruvinel@gmail.com."
}
},
{
"@type": "Person",
"name": "Paulo Luiz Carvalho Francescantonio",
"url": "https://questionsmedicales.fr/author/Paulo%20Luiz%20Carvalho%20Francescantonio",
"affiliation": {
"@type": "Organization",
"name": "School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil."
}
},
{
"@type": "Person",
"name": "Alessandra Dellavance",
"url": "https://questionsmedicales.fr/author/Alessandra%20Dellavance",
"affiliation": {
"@type": "Organization",
"name": "Research and Development Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil."
}
},
{
"@type": "Person",
"name": "Luis Eduardo Coelho Andrade",
"url": "https://questionsmedicales.fr/author/Luis%20Eduardo%20Coelho%20Andrade",
"affiliation": {
"@type": "Organization",
"name": "Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. luis.andrade@unifesp.br."
}
},
{
"@type": "Person",
"name": "Antônio Carlos Ximenes",
"url": "https://questionsmedicales.fr/author/Ant%C3%B4nio%20Carlos%20Ximenes",
"affiliation": {
"@type": "Organization",
"name": "Hospital Geral de Goiânia Alberto Rassi, Goiânia, GO, Brazil."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The systemic renin-angiotensin system in COVID-19.",
"datePublished": "2022-11-22",
"url": "https://questionsmedicales.fr/article/36418458",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-022-24628-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Lymphatic vessels and the renin-angiotensin-system.",
"datePublished": "2023-08-11",
"url": "https://questionsmedicales.fr/article/37565265",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1152/ajpheart.00023.2023"
}
},
{
"@type": "ScholarlyArticle",
"name": "Targeting the renin angiotensin system for respiratory diseases.",
"datePublished": "2023-03-21",
"url": "https://questionsmedicales.fr/article/37524485",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/bs.apha.2023.02.002"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Effect of components of the renin-angiotensin system, rs2106809 polymorphism of the",
"datePublished": "2023-08-30",
"url": "https://questionsmedicales.fr/article/37694864",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.14341/probl13274"
}
},
{
"@type": "ScholarlyArticle",
"name": "Regulation of the renin-angiotensin-aldosterone system by cyclic nucleotides and phosphodiesterases.",
"datePublished": "2023-08-22",
"url": "https://questionsmedicales.fr/article/37674612",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fendo.2023.1239492"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Cellules",
"item": "https://questionsmedicales.fr/mesh/D002477"
},
{
"@type": "ListItem",
"position": 3,
"name": "Cellules épithéliales",
"item": "https://questionsmedicales.fr/mesh/D004847"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hépatocytes",
"item": "https://questionsmedicales.fr/mesh/D022781"
},
{
"@type": "ListItem",
"position": 5,
"name": "Cellules HepG2",
"item": "https://questionsmedicales.fr/mesh/D056945"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Cellules HepG2 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Cellules HepG2",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Cellules HepG2",
"description": "Comment identifier les cellules HepG2 en laboratoire ?\nQuelles techniques sont utilisées pour étudier les HepG2 ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Renin-Angiotensin+System#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Cellules HepG2",
"description": "Les cellules HepG2 présentent-elles des symptômes ?\nQuels marqueurs sont associés aux cellules HepG2 ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Renin-Angiotensin+System#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Cellules HepG2",
"description": "Les cellules HepG2 peuvent-elles aider à prévenir des maladies ?\nComment les HepG2 contribuent-elles à la recherche préventive ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Renin-Angiotensin+System#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Cellules HepG2",
"description": "Peut-on utiliser HepG2 pour tester des médicaments ?\nComment les HepG2 aident-elles à développer des traitements ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Renin-Angiotensin+System#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Cellules HepG2",
"description": "Quelles complications peuvent être étudiées avec HepG2 ?\nLes HepG2 aident-elles à comprendre les complications du foie ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Renin-Angiotensin+System#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Cellules HepG2",
"description": "Quels facteurs de risque sont étudiés avec HepG2 ?\nComment HepG2 aide à identifier des facteurs de risque ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Renin-Angiotensin+System#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les cellules HepG2 en laboratoire ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cellules HepG2 peuvent être identifiées par leur morphologie et leur marqueur spécifique, l'alpha-fœtoprotéine."
}
},
{
"@type": "Question",
"name": "Quelles techniques sont utilisées pour étudier les HepG2 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les techniques incluent la culture cellulaire, la microscopie et les tests de viabilité cellulaire."
}
},
{
"@type": "Question",
"name": "Les cellules HepG2 présentent-elles des symptômes ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cellules HepG2 ne présentent pas de symptômes, car elles sont des cellules in vitro."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés aux cellules HepG2 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cellules HepG2 expriment des marqueurs comme l'alpha-fœtoprotéine et des enzymes hépatiques."
}
},
{
"@type": "Question",
"name": "Les cellules HepG2 peuvent-elles aider à prévenir des maladies ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont utilisées pour étudier les effets préventifs de composés sur les maladies hépatiques."
}
},
{
"@type": "Question",
"name": "Comment les HepG2 contribuent-elles à la recherche préventive ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'analyser les effets de l'alimentation et des toxines sur la santé hépatique."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser HepG2 pour tester des médicaments ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les cellules HepG2 sont souvent utilisées pour évaluer la toxicité et l'efficacité des médicaments."
}
},
{
"@type": "Question",
"name": "Comment les HepG2 aident-elles à développer des traitements ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'étudier les mécanismes d'action des médicaments sur le foie et d'identifier des cibles thérapeutiques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent être étudiées avec HepG2 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications liées aux maladies hépatiques, comme la cirrhose et le cancer du foie, peuvent être modélisées."
}
},
{
"@type": "Question",
"name": "Les HepG2 aident-elles à comprendre les complications du foie ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont essentielles pour étudier les mécanismes des complications hépatiques."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont étudiés avec HepG2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque comme l'alcool, les médicaments et les toxines sont souvent analysés."
}
},
{
"@type": "Question",
"name": "Comment HepG2 aide à identifier des facteurs de risque ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'évaluer l'impact de divers agents sur la santé des cellules hépatiques."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 05/02/2025
Contenu vérifié selon les dernières recommandations médicales
5 publications dans cette catégorie
Affiliations :
School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil. melocruvinel@gmail.com.
Publications dans "Cellules HepG2" :
5 publications dans cette catégorie
Affiliations :
School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil.
Publications dans "Cellules HepG2" :
4 publications dans cette catégorie
Affiliations :
Research and Development Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil.
Publications dans "Cellules HepG2" :
4 publications dans cette catégorie
Affiliations :
Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. luis.andrade@unifesp.br.
Immunology Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil. luis.andrade@unifesp.br.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Hospital Geral de Goiânia Alberto Rassi, Goiânia, GO, Brazil.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Departamento de Patologia Clínica e Anatomia Patológica, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Faculdade de Medicina, Hospital das Clinicas HCFMUSP, Universidade de Sao Paulo, São Paulo, SP, Brazil.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Department of Clinical Pathology, School of Medicine, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
Hermes Pardini Group, Vespasiano, MG, Brazil.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Serviço de Reumatologia e Laboratório de Autoimunidade da Divisão de Laboratório Central do Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Sociedade Brasileira de Autoimunidade, Porto Alegre, RS, Brazil.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory of Marine Resource Utilization in South China Sea, School of Materials Science and Engineering, Hainan University, Haikou 570228, China. Electronic address: liv880213@foxmail.com.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
Hainan Provincial Key Laboratory for Tropical Hydrobiology and Biotechnology, School of Marine Science, Hainan University, Haikou 570228, China. Electronic address: xiexi@hainu.edu.cn.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory of Marine Resource Utilization in South China Sea, School of Materials Science and Engineering, Hainan University, Haikou 570228, China. Electronic address: 1532892231@qq.com.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory of Marine Resource Utilization in South China Sea, School of Materials Science and Engineering, Hainan University, Haikou 570228, China. Electronic address: luolijie4567@163.com.
Publications dans "Cellules HepG2" :
SARS-CoV-2 gains cell entry via angiotensin-converting enzyme (ACE) 2, a membrane-bound enzyme of the "alternative" (alt) renin-angiotensin system (RAS). ACE2 counteracts angiotensin II by converting ...
The lymphatic system is an integral part of the circulatory system and plays an important role in the fluid homeostasis of the human body. Accumulating evidence has recently suggested the involvement ...
Renin-angiotensin system (RAS) plays an indispensable role in regulating blood pressure through its effects on fluid and electrolyte balance. As an aside, cumulative evidence from experimental to clin...
Angiotensin-converting enzyme 2 (ACE2) is a key component of the renin-angiotensin system (RAS), providing counter-regulation of its effects and, simultaneously, a receptor for the SARS-CoV-2 entering...
The aim of the study was to investigate the effect of RAS components, the relationship of ACE2 gene polymorphism rs2106809 and ACEi/ARBs therapy with the COVID-19 severity....
The study included patients with COVID-19 hospitalized in Endocrinology research centre (n = 173), who were divided into groups of moderate and severe course. Determination of RAS components was perfo...
The groups differed significantly in age, blood glucose levels, and inflammatory markers: leukocytes, neutrophils, IL-6, D-dimer, C-reactive protein, ferritin and liver enzymes, which correlated with ...
In our study, the influence of activation of RAS components (ACE, ACE2, AT II, ADAM17) and ACE2 gene polymorphism on the severity of COVID-19 course was not confirmed. The severity of COVID-19 course ...
The renin-angiotensin-aldosterone system (RAAS) is one of the key players in the regulation of blood volume and blood pressure. Dysfunction of this system is connected with cardiovascular and renal di...
Renin-angiotensin system (RAS) inhibitors - including angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) - slow the progression of mild or moderate chronic kidney ...
In this multicenter, open-label trial, we randomly assigned patients with advanced and progressive chronic kidney disease (eGFR, <30 ml per minute per 1.73 m...
At 3 years, among the 411 patients who were enrolled, the least-squares mean (±SE) eGFR was 12.6±0.7 ml per minute per 1.73 m...
Among patients with advanced and progressive chronic kidney disease, the discontinuation of RAS inhibitors was not associated with a significant between-group difference in the long-term rate of decre...
Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, the possible roles of renin-angiotensin system (RAS) inhibitors in COVID-19 have been debated as favorable, harmful, or neutral. An...
Traumatic brain injury (TBI) is a major public health problem, with limited pharmacological options available beyond symptomatic relief. The renin angiotensin system (RAS) is primarily known as a syst...
It has been our pleasure to have been able to develop two special issues within the International Journal of Molecular Sciences:...
Brain neurodegenerative diseases (BND) are debilitating conditions that are especially characteristic of a certain period of life and considered major threats to human health. Current treatments are l...